Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

11 Jun 2019

No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.

Taking a daily vitamin D supplement does not prevent type 2 diabetes in adults at high risk, according to results from a study funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The Vitamin D and Type 2 Diabetes (D2d) study enrolled 2,423 adults and was conducted at 22 sites across the US. These findings were published in the New England Journal of Medicine and presented at the 79th Scientific Sessions of the American Diabetes Association in San Francisco.

Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

D2d is the largest study to directly examine if daily vitamin D supplementation helps keep people at high risk for type 2 diabetes from developing the disease. The study included adults aged 30 or older and assigned participants randomly to either take 4,000 International Units (IU) of the D3 (cholecalciferol) form of vitamin D or a placebo pill daily. All study participants had their vitamin D levels measured at the start of the study. At that time, about 80% of participants had vitamin D levels considered sufficient by US nutritional standards.

“Observational studies have reported an association between low levels of vitamin D and increased risk for type 2 diabetes,” said Myrlene Staten, D2d project scientist at NIDDK. “Additionally, smaller studies found that vitamin D could improve the function of beta cells, which produce insulin. However, whether vitamin D supplementation may help prevent or delay type 2 diabetes was not known.”

The study screened participants every 3 to 6 months for an average of 2.5 years to determine whether diabetes had developed. Researchers then compared the number of people in each of the two study groups that had progressed to type 2 diabetes. At the end of the study, 293 out of 1211 participants (24.2%) in the vitamin D group developed diabetes compared to 323 out of 1212 (26.7%) in the placebo group – a difference that did not reach statistical significance. The study was designed to detect a risk reduction of 25% or more.

“In addition to the study’s size, one of its major strengths is the diversity of its participants, which enabled us to examine the effect of vitamin D across a large variety of people,” said lead author Anastassios G. Pittas, principal investigator from Tufts Medical Center, Boston. “When the study ended, we found no meaningful difference between the two groups regardless of age, sex, race or ethnicity.”

Read More

Related news

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

6 Jun 2019

Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.

Read more 
Lilly gets its hands on non-opioid pain asset

Lilly gets its hands on non-opioid pain asset

4 Jun 2019

Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.

Read more 
Updated clinical trial simulation software saves time and money

Updated clinical trial simulation software saves time and money

3 Jun 2019

One customer saves $25m and 3 years' development time in their clinical development strategy.

Read more 
Merck bolsters oncology pipeline with acquisition

Merck bolsters oncology pipeline with acquisition

22 May 2019

Acquisition includes novel late-stage renal cell carcinoma candidate, PT2977.

Read more 
Follicum files patent application for new topical formulation for hair loss

Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more